The NICE British National Formulary (BNF) and British National Formulary for Children (BNFc) sites are only available to users in the UK, Crown Dependencies and British Overseas Territories. If you believe you are seeing this page in error please contact us. Ciprofloxacin is an antibiotic that belongs to the family of medications known as quinolones. It is used to treat infections caused by certain bacteria. It is most commonly used to treat infections of the skin, sinuses, bone, lung, abdomen, kidney, prostate, and bladder. It can also be used to treat some sexually transmitted infections (STIs), some forms of infectious diarrhea, and typhoid fever. The extended release form of ciprofloxacin is used to treat bladder and kidney infections. This medication may be available under multiple brand names and/or in several different forms. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here.
Antibiotic Class: Quinolone Antimicrobial Spectrum: Gram-positive: methicillin-susceptible Staphylococcus aureus (MSSA) (lowest quinolone activity vs. MSSA), Streptococcus pneumoniae Gram-negative: Enterobacteriaceae, H. Pharmacokinetics: Dose of 750mg; Cmax: 3.5mg/ml; Volume of distribution: 3.2 L/kg; Table 2 & Table 3 Adverse Effects: CNS: headache, insomnia, dizziness; hallucinations, depression, psychotic reactions (rare) Connective tissue: tendon injury Renal: interstitial nephritis Cardiovascular: QTC prolongation, torsades de pointes, arrhythmias Dosage: Tablets: 100mg, 250mg, 500mg, 750mg, 500mg extended release tabs, 1000mg extended release tablets IV: 200mg, 400mg Suspension: 250mg/5ml and 500mg/5ml (both in 100ml bottles) Adult patients: Lower respiratory tract infections: 500-750mg PO q12h / 400mg q8-12h IV x 7-14 days Acute sinusitis: 500mg PO q12h / 400mg q12h IV x 10 days Nosocomial pneumonia: 400mg IV q8h x 10-14 days Uncomplicated UTI: 250mg PO q12h x 3 days 500mg extended release tablets q24h Complicated UTI/Pyelonephritis: 500mg PO q12h / 400mg IV q12h x 7-14 days 1000mg extended release tablets q24h Prostatits: 500mg PO q12h / 400mg IV q12h x 28 days Uncomplicated gonococcal infections: 500mg PO x 1 dose Chancroid: 500mg PO q12h x 3 doses Uncomplicated skin/skin structure: 500-750mg PO q12h x 7-14 days / 400mg IV q8-12h Intra-abdominal infections: 500mg PO q12h x 7-14days / 400mg IV q12h Infectious diarrhea: 500mg q12h x 3-5 days (current recommendations) 500mg PO q12h x 5-7 days (labeled) Inhalational anthrax (post-exposure): 500mg PO q12h x 60 days Febrile neutropenia: 400mg IV q8h Pediatrics: Complicated UTI/Pyelonephritis: 6-10mg/kg not to exceed 400mg per dose q8h x 10-21 days 10-20mg/kg not to exceed 750mg per dose q12h x 10-21 days Inhalational anthrax (post-exposure): 10mg/kg not to exceed 400mg per dose q12h x 60 days 15mg/kg not to exceed 500mg per dose q12h x 60 days Table 4 Disease state based dosing: Renal failure: IV: Cr Cl 30 m L/min or greater, give usual dose; Cr Cl 5-29 m L/min, 200-400 mg IV every 18-24 hr ORAL: Cr Cl greater than 50 m L/min, give usual dose; Cr Cl 30-50 m L/min, 250-500 mg every 12 hr; Cr Cl 5-29 m L/min, 250-500 mg every 18 hr Hepatic failure: No dosing changes recommended at this time. Pharmacodynamics: Fluoroquinolones produce both (peak: MIC), and a combination of concentration and time-dependent killing (AUC: MIC). maltophilia Atypicals: Legionella pneumophilia Mechanism of Action: Inhibition of topoisomerase (DNA gyrase) enzymes, which inhibits relaxation of supercoiled DNA and promotes breakage of double stranded DNA. The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE If ' Ready-to-Use' prep not available: [200 mg] [100 ml] [1 hour] [400 mg] [250 ml] [1 hour] Primary: -------Ready to Use------------ Ciprofloxacin in 5% dextrose injection, USP is available in 200 mg and 400 mg strengths. The 2 mg/m L infusion solution is supplied in latex-free flexible containers as follows: Ciprofloxacin injection should be administered to adults by intravenous infusion over a period of 60 minutes at dosages described in the Dosage Guidelines table. Slow infusion of a dilute solution into a larger vein will minimize patient discomfort and reduce the risk of venous irritation. (See Preparation of Ciprofloxacin Injection for Administration section.) The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient’s host-defense mechanisms, and the status of renal and hepatic function. ADULT DOSAGE GUIDELINES Drug administration should begin as soon as possible after suspected or confirmed exposure. This indication is based on a surrogate endpoint, ciprofloxacin serum concentrations achieved in humans, reasonably likely to predict clinical benefit.4 For a discussion of ciprofloxacin serum concentrations in various human populations, see INHALATIONAL ANTHRAX — ADDITIONAL INFORMATION.
Apply 0.25 mL twice daily for 7 days, each 0.25 mL dose contains 0.5 mg ciprofloxacin. For Adult. 400 mg every 8–12 hours, to be given over 60 minutes. The pharmacokinetics of 400 mg of ciprofloxacin given intravenously i.v. every 8 h q8h in severely septic adults was documented in a multidisciplinary, tertiary.